(Q39847114)

15 September 2017

title

Seasonal influenza vaccinations: specialized products for different target groups (English)

1 reference

15 September 2017

1

Arnold S Monto

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

15 September 2017

1 reference

15 September 2017

volume

28 Suppl 4

1 reference

15 September 2017

page(s)

D14-23

1 reference

ANTIBODY RESPONSE OF HUMAN BEINGS FOLLOWING VACCINATION WITH INFLUENZA VIRUSES.

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Influenza vaccine--outmaneuvering antigenic shift and drift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Mapping the antigenic and genetic evolution of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Comparative efficacy of inactivated and live attenuated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Influenza-associated hospitalizations in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Effectiveness of influenza vaccine in the community-dwelling elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Detection and control of influenza outbreaks in well-vaccinated nursing home populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

The unmet need in the elderly: designing new influenza vaccines for older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

CLINICAL TRIALS OF OIL-ADJUVANT INFLUENZA VACCINES, 1960-3. REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS COMMITTEE ON INFLUENZA AND OTHER RESPIRATORY VIRUS VACCINES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966--1971

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

An influenza simulation model for immunization studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

The Japanese experience with vaccinating schoolchildren against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.025

10.1016/J.VACCINE.2010.08.025

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference